Eli Lilly's Retatrutide Fakes Flood UK Black Market — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Retatrutide remains in Phase III clinical trials with no approval from any regulatory body, and only 50% of Phase III drugs in the US are eventually approved by the FDA.
- Counterfeit "reta" is being sold openly in UK gyms, nail and beauty salons, hairdressers, on social media and even by street flower sellers, with users publicly discussing dealers and posting before-and-after shots on TikTok.
- Eli Lilly has reported more than 14,000 websites, advertisements and social media posts it says are illegally marketing retatrutide, and says it is working with law enforcement to combat black market sales.
- The UK MHRA has carried out raids and seizures over the past year, working to disrupt illegal importation and distribution routes.
- Endocrinologist Prof Donal O'Shea reports young, fit patients arriving in hospital with nausea, vomiting, diarrhoea and in some cases kidney failure, and says some personal trainers are not only supplying clients with the drug but injecting them too.
- Retatrutide would be the first weight-loss medication to act on three hormone receptors—GLP-1, GIP and glucagon—earning it the nickname the "triple G."
- Eli Lilly plans to submit its US FDA application early next year, with the earliest possible US availability end of 2027 and UK availability possibly 2028.
Why it matters: Eli Lilly has spent nearly a decade developing retatrutide yet now faces a global shadow market operating years ahead of any legitimate approval, forcing the company into an enforcement fight over an asset that still might never reach patients. For users, doctors report hospitalisations—including kidney failure—from a drug whose safety profile is not yet established, taken with zero dosing oversight.
Ask SkimNews
